ENPP2 and pulmonary fibrosis: Meanwhile, the lysophosphatidic acid (LPA) pathway is emerging as an important mediator in the pathogenesis of cancer and fibrosis; of note, the inhibitors of LPA-producing enzyme autotaxin and LPA receptors have showed an encouraging efficacy during phase II clinical trials in patients with pulmonary fibrosis [64,65].